Drugs for Complement Component 3 Deficiency, Autosomal Recessive (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 200)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Benzocaine |
Approved, Investigational |
Phase 4 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
2 |
|
Tannic acid |
Approved |
Phase 4 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
3 |
|
Midazolam |
Approved, Illicit |
Phase 4 |
|
59467-70-8 |
4192 |
Synonyms:
Buccolam
Buccolam®|Dormicum®|Nayzilam®|USL261 (nasal spray formulation)|Versed®
Dea no. 2884
Dormicum
Hydrochloride, midazolam
Maleate, midazolam
Mezolam
Midazolam
Midazolam base
MIDAZOLAM CIV
|
Midazolam Hcl
Midazolam hydrochloride
Midazolam maleate
Midazolamum
Midazolamum [INN-Latin]
Nayzilam
USL261
USL-261
Versed
|
|
4 |
|
Morphine |
Approved, Investigational |
Phase 4 |
|
57-27-2 |
5288826 |
Synonyms:
(-)-Heroin hydrochloride
(-)-Morphine
(−)-MORPHINE
(5a,6a)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5a,6a)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5Α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5Α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
ANHYDROUS MORPHINE
Apokyn
Astramorph PF
AVINZA
Chloride, morphine
Contin, MS
D-(-)-Morphine
DEPODUR
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dulcontin
Duramorph
Duramorph PF
Duromorph
Epimorph
Heroin hydrochloride
Heroine hydrochloride
IDS-NM-009
INFUMORPH
KADIAN
l-Morphine
M.O.S
Meconium
M-Eslon
Morfina
Morfina dosa
|
Morphia
Morphin
Morphina
MORPHINE
Morphine chloride
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine sulfate
Morphine sulfate (2:1), anhydrous
Morphine sulfate (2:1), pentahydrate
morphine sulfate|Ms Contin®|Oramorph®
Morphinism
Morphinum
Morphitec
Morphium
Moscontin
MS Contin
MS/L
MS/S
MSIR
N02AA01
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
ORAMORPH
Oramorph SR
Ospalivina
Rescudose
RMS Uniserts
Roxanol
Roxanol 100
Roxanol UD
Statex
Statex Drops
Substitol
Sulfate, morphine
|
|
5 |
|
Aminosalicylic acid |
Approved |
Phase 4 |
|
65-49-6 |
4649 |
Synonyms:
2-HYDROXY-4-aminobenzoate
2-HYDROXY-4-aminobenzoIC ACID
4 Aminosalicylic acid
4-amino-2-hydroxybenzoic acid
4-Aminosalicylate
4-Aminosalicylic acid
4-ASA
Acid, aminosalicylic
Alumino 4 aminosalicylic acid
Alumino-4-aminosalicylic acid
Amino-pas
Aminosalicylate
Aminosalicylate sodium
Aminosalicylic acid
APAS
p Aminosalicylic acid
p Aminosalicylic acid monolithium salt
p Aminosalicylic acid monopotassium salt
|
p Aminosalicylic acid monosodium salt
p-Aminosalicylate
p-Aminosalicylic acid
p-Aminosalicylic acid monolithium salt
p-Aminosalicylic acid monopotassium salt
p-Aminosalicylic acid monosodium salt
p-Aminosalicylic acid, aluminum (2:1) salt
p-Aminosalicylic acid, calcium (2:1) salt
p-Aminosalicylic acid, monosodium salt, dihydrate
Pamisyl
Para aminosalicylic acid
Para-amino salicylate
Para-amino salicylic acid
Para-aminosalicylic acid
PAS
Paser
PASK
Rezipas
|
|
6 |
|
Mesalazine |
Approved |
Phase 4 |
|
89-57-6 |
4075 |
Synonyms:
3-Carboxy-4-hydroxyaniline
5 Aminosalicylate
5 Aminosalicylic acid
5-Aminosalicylate
5-Aminosalicylic acid
5-aminosalicylic acid|5-ASA|mesalamine (USAN)|Pentasa®
5-ASA
Allphar brand OF mesalamine
Antigen brand OF mesalamine
Apriso
Asacol
ASACOL HD
Asacolitin
Asacolon
Ascolitin
Axcan brand OF mesalamine
Byk brand OF mesalamine
Canasa
Celltech brand OF mesalamine
Claversal
COLTEC EC
Delzicol
Falk brand OF mesalamine
Farmasa brand OF mesalamine
Ferring brand OF mesalamine
Fisalamine
Fivasa
GlaxoSmithKline brand OF mesalamine
Henning berlin brand OF mesalamine
Hydrochloride, mesalamine
Iialda
IPOCOL
Lialda
Lixacol
m Aminosalicylic acid
m-Aminosalicylate
m-Aminosalicylic acid
|
MAX-002
Merckle brand OF mesalamine
Mesalamine
Mesalamine hydrochloride
Mesalamine monosodium salt
Mesalazina
Mesalazine
Mésalazine
Mesalazinum
Mesasal
MESREN MR
Meta aminosalicylic acid
Meta-aminosalicylic acid
MEZAVANT XL
Monosodium salt, mesalamine
Norgine brand OF mesalamine
Novo 5 asa
Novo5 asa
Novo-5 asa
Novopharm brand OF mesalamine
NSC-38877
OCTASA
p-Aminosalicylsaeure
Pentasa
PENTASA SR
Procter and gamble brand OF mesalamine
Provalis brand OF mesalamine
Rowasa
Salofalk
Sanofi synthelabo brand OF mesalamine
Schering plough brand OF mesalamine
Schering-plough brand OF mesalamine
Sfrowasa
SmithKline brand OF mesalamine
Solvay brand OF mesalamine
Yamanouchi brand OF mesalamine
|
|
7 |
|
Azithromycin |
Approved |
Phase 4 |
|
83905-01-5 |
447043 |
Synonyms:
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
Azadose
AZASITE
Azenil
Azifast
Azigram
Azimakrol
Azithramycine
AZITHROMYCIN
AZITHROMYCIN ANHYDROUS
Azithromycin dihydrate
AZITHROMYCIN HYDRATE
Azithromycin monohydrate
Azithromycin pfizer brand
Azithromycine
Azithromycinum
Azitrocin
Azitromicina
Azitromin
AZYTER
Azythromycin
Bayer brand OF azithromycin dihydrate
CLAMELLE
CP 62993
|
CP-62,993
CP-62993
Dihydrate, azithromycin
Funk brand OF azithromycin dihydrate
Goxal
Hemomycin
Lesvi brand OF azithromycin dihydrate
Mack brand OF azithromycin dihydrate
Monohydrate, azithromycin
Pfizer brand OF azithromycin
Pfizer brand OF azithromycin dihydrate
Pharmacia brand OF azithromycin dihydrate
Sumamed
SUNAMED
Toraseptol
Ultreon
Vinzam
Vita brand OF azithromycin dihydrate
XZ 405
XZ 450
XZ-450
Zentavion
Zithromax
Zitromax
Zmax
|
|
8 |
|
Anti-Anxiety Agents |
|
Phase 4 |
|
|
|
9 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
10 |
|
Anesthetics, Intravenous |
|
Phase 4 |
|
|
|
11 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
12 |
|
GABA Modulators |
|
Phase 4 |
|
|
|
13 |
|
Analgesics, Opioid |
|
Phase 4 |
|
|
|
14 |
|
Narcotics |
|
Phase 4 |
|
|
|
15 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
16 |
|
Antitubercular Agents |
|
Phase 4 |
|
|
|
17 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
18 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
19 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
20 |
|
Analgesics |
|
Phase 4 |
|
|
|
21 |
|
Anti-Bacterial Agents |
|
Phase 4 |
|
|
|
22 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
23 |
|
Antiviral Agents |
|
Phase 4 |
|
|
|
24 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
25 |
|
Immunoglobulins |
|
Phase 4 |
|
|
|
26 |
|
Antibodies |
|
Phase 4 |
|
|
|
27 |
|
Vaccines |
|
Phase 4 |
|
|
|
28 |
|
Heptavalent Pneumococcal Conjugate Vaccine |
|
Phase 4 |
|
|
|
29 |
|
Abrocitinib |
Approved, Investigational |
Phase 3 |
|
1622902-68-4 |
78323835 |
Synonyms:
ABROCITINIB
Cibinqo®|compound 25 [PMID: 29298069]|PF-04965842|PF04965842
|
N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide
PF-04965842
|
|
30 |
|
Pentoxifylline |
Approved, Investigational |
Phase 3 |
|
6493-05-6 |
4740 |
Synonyms:
Agapurin
BL-191
BL-191|Trental®
C04AD03
EHT0201
NEOTREN MR
NSC-637086
Oxpentifylline
Pentoxifilina
|
Pentoxifyllin
Pentoxifylline
Pentoxifyllinum
Pentoxil
Torental
Trental
TRENTAL 100
TRENTAL 400
|
|
31 |
|
Aluminum sulfate |
Approved |
Phase 3 |
|
10043-01-3 |
|
Synonyms:
Aluminium sulfate
Aluminium sulfate anhydrous
Aluminum sulfate anhydrous
|
Aluminum sulphate anhydrous
Dialuminum sulfate
Dialuminum trisulfate
|
|
32 |
|
Aluminum hydroxide |
Approved, Investigational |
Phase 3 |
|
21645-51-2 |
|
Synonyms:
Al(OH)3
Aldrox
Algeldrate
Algeldrate atlas brand
Algeldrate axcan brand
Algeldrate chefaro brand
Algeldrate roques brand
Algeldrate stiefel brand
Algeldrate whitehall brand
Algeldrate wyeth brand
Alhydrogel
ALterna gel
Alugel
Alumina, hydrated
Aluminio hidróxido
Aluminium hydroxide
Aluminium hydroxide gel, dried
Aluminium hydroxide, dried
Aluminiumhydroxid
Aluminum hydroxide
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Amphojel
|
Atlas brand OF algeldrate
Axcan brand OF algeldrate
Basalgel
Brasivil
chefaro Brand OF algeldrate
Dialume
Dried aluminium hydroxide
Dried aluminum hydroxide gel
Dried aluminum hydroxide gel fine granules
Hydrated alumina
Hydroxide, aluminum
Nephrox
Pepsamer
Rhône poulenc rorer brand OF algeldrate
Rhône-poulenc rorer brand OF algeldrate
Rocgel
Roques brand OF algeldrate
Sanofi winthrop brand OF algeldrate
SmithKline beecham brand OF algeldrate
Stiefel brand OF algeldrate
Whitehall brand OF algeldrate
Wyeth brand OF algeldrate
|
|
33 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2, Phase 3 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
34 |
|
Busulfan |
Approved, Investigational |
Phase 2, Phase 3 |
|
55-98-1 |
2478 |
Synonyms:
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulphonoxy)butane
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulfonic acid
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethanesulphonic acid
1,4-Dimesyloxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulphonoxybutane
Bisulfex
Bisulphex
BUSILVEX
BUSULFAN
Busulfan glaxosmithkline brand
Busulfan orphan brand
Busulfan wellcome
Busulfan wellcome brand
Busulfano
Busulfanum
Busulfex
BUSULFEX IV
Busulphan
Busulphane
Busulphano
Busulphanum
Butanedioldimethanesulfonate
Buzulfan
Citosulfan
Glaxo wellcome brand OF busulfan
GlaxoSmithKline brand OF busulfan
Glyzophrol
Leucosulfan
|
Leucosulphan
Mablin
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
Myeleukon
Myeloleukon
Myelosan
Mylecytan
Myleran
Myléran
Myleran Tablets
N-Butane-1,3-di(methylsulfonate)
NCI-C01592
NSC-750
Orphan brand OF busulfan
Sulfabutin
Sulphabutin
Tetramethylene bis(methanesulfonate)
Tetramethylene bis(methanesulfonic acid)
Tetramethylene bis(methanesulphonate)
Tetramethylene bis(methanesulphonic acid)
Tetramethylene dimethane sulfonate
Tetramethylenester kyseliny methansulfonove
Wellcome brand OF busulfan
Wellcome, busulfan
|
|
35 |
|
Cholecalciferol |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
67-97-0, 1406-16-2 |
5280795 10883523 |
Synonyms:
(+)-Vitamin D3
(1S,3Z)-3-[(2E)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-1-CYCLOHEXANOL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENECYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-{2-[(1R,4E,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXAN-1-OL
(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3BETA,Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
(3Β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5E,7E)-9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
(5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
3-BETA,Z,7E-9,10-SECOCHOLESTR-5,7,10(19)-TRIEN-3-OL
7-DEHYDROCHOLESTEROL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
ACCRETE D3
ACIFEROL D3
ACTIVATED
Activated 7-dehydrocholesterol
ADCAL-D3
ARACHITOL
AVITICOL
BIOLIFE VITAMIN D3
BIO-VITAMIN D3
CACIT D3
CALCEOS
CALCICHEW D3
CALCICHEW D3 FTE
CALCICHEW D3 ONCE DAILY
CALCI-D
Calciferol
Calciol
CALDRINK D3
CALFOVIT D3
CC
Cholecalciferol
CHOLECALCIFEROL D3
Cholecalciferols
Cholecalciferolum
COLECAL D3
Colecalciferol
Colecalciferolum
COLEKAL-D3
COLEVIT D3
CUBICOLE D3
D3 LEMON MELTS
D3-50
D3-VIGANTOL
DEKRISTOL
DELSTEROL
Delta-D
DEPARAL
DESUNIN
DEVARON
Dihydrocholesterol
DLUX 400
D-MAX
D-TRACETTEN
|
D-VIT3
EBIVIT
E-D3
EVACAL D3
FERACOL
FULTIUM DAILY D3
FULTIUM-D3
GRANUVIT D3
HUX D3
INVITA D3
ISO D3
KORA LIQUID
MICRO-DEE
NATECAL D3
NATURE'S REMEDY VITAMIN D3
NEO-D
NPHD3
NSC-375571
Oleovitamin D3
OSTEOCAPS D3
PLENACHOL
PRO D3
PRO D3 FOLIC
PRO D3 FORTE
PROVITINA
QUINTOX
RICKETON
ROYALVIT D3
STEXEROL-D3
STIVIT-D3
SUNVIT-D3 1,000
SUNVIT-D3 10,000
SUNVIT-D3 2,000
SUNVIT-D3 20,000
SUNVIT-D3 3,000
SUNVIT-D3 400
SUNVIT-D3 5,000
SUNVIT-D3 50,000
SUNVIT-D3 800
SYNERVIT-D3
THEICAL D-3
THORENS
TRIVITAN
VIDDE-3-HYDROSOL
VI-DE3
VIDEKHOL
VIGANTOL
VIGANTOLETTEN
VIGANTOLETTEN 500
VIGORSAN
VIT D3 STREULI
VITA-D3
VITAMIN D
Vitamin D 3
VITAMIN D ASSAY SYSTEM SUITABILITY
Vitamin D NOS
Vitamin D, unspecified form
Vitamin D3
Vitamin D-3
VITINC DAN-DEE-3
ZYMAD
δ-D
|
|
36 |
|
Glutamic acid |
Approved, Nutraceutical |
Phase 3 |
|
56-86-0 |
33032 |
Synonyms:
(+)-Estrone
(1S)-2-[(3-O-b-D-Glucopyranosyl-b-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoate
(1S)-2-[(3-O-b-D-Glucopyranosyl-b-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(1S)-2-[(3-O-beta-D-Glucopyranosyl-beta-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(1S)-2-[(3-O-Β-D-glucopyranosyl-β-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoate
(1S)-2-[(3-O-Β-D-glucopyranosyl-β-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(2R)-2,3-Dihydroxypropanoic acid
(2S)-2-Aminopentanedioate
(2S)-2-Aminopentanedioic acid
(3R,4S,5R)-5-[(1R)-1-Carboxy-2,2-difluoro-1-(phosphonooxy)ethoxy]-4-hydroxy-3-(phosphonooxy)cyclohex-1-ene-1-carboxylate
(R)-2,3-Dihydroxypropanoic acid
(R)-Glycerate
(R)-Glyceric acid
(S)-(+)-Glutamate
(S)-(+)-Glutamic acid
(S)-2-Aminopentanedioate
(S)-2-Aminopentanedioic acid
(S)-Glutamate
(S)-Glutamic acid
1,3,5(10)-Estratrien-3-ol-17-one
1-Amino-2-hydroxyethane
1-Aminopropane-1,3-dicarboxylate
1-Amino-propane-1,3-dicarboxylate
1-Aminopropane-1,3-dicarboxylic acid
1-Amino-propane-1,3-dicarboxylic acid
2 Acetamido 2 deoxy D glucose
2 Acetamido 2 deoxyglucose
2 Aminoethanol
2-Acetamido-2-deoxy-D-glucose
2-Acetamido-2-deoxyglucose
2-Amino-1-ethanol
2-Aminoethan-1-ol
2-Aminoethanol
2-Amino-ethanol
2-Aminoethyl alcohol
2-Aminoglutarate
2-Aminoglutaric acid
2-Aminopentanedioate
2-Aminopentanedioic acid
2-Ethanolamine
2-Hydroxyethanamine
2-Hydroxyethylamine
3a,7a,12a-Trihydroxy-5b-cholan-24-oylglycine
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oylglycine
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid-24-glycine
3alpha,7alpha,12alpha-Trihydroxy-N-(carboxymethyl)-5beta-cholan-24-amide
3-Hydroxy-1,3,5(10)-estratrien-17-one
3-Hydroxy-17-keto-estra-1,3,5-triene
3-Hydroxyestra-1,3,5(10)-trien-17-one
3-Hydroxyestra-1,3,5(10)-triene-17-one
3-Hydroxyoestra-1,3,5(10)-trien-17-one
3Α,7α,12α-trihydroxy-5β-cholan-24-oylglycine
3Α,7α,12α-trihydroxy-5β-cholanic acid-24-glycine
3Α,7α,12α-trihydroxy-N-(carboxymethyl)-5β-cholan-24-amide
a,b-Hydroxypropionate
a,b-Hydroxypropionic acid
a-Aminoglutarate
a-Aminoglutaric acid
Acetylglucosamine
Acide glutamique
Acido glutamico
ácido glutámico
Acidum glutamicum
Aciglut
Aethanolamin
a-Glutamate
a-Glutamic acid
alpha,beta-Hydroxypropionate
alpha,beta-Hydroxypropionic acid
alpha-Aminoglutarate
alpha-Aminoglutaric acid
alpha-Glutamate
alpha-Glutamic acid
Aluminum L glutamate
Aluminum L-glutamate
Aminoethanol
Aminoglutarate
Aminoglutaric acid
b-Aminoethanol
b-Aminoethyl alcohol
beta-Aminoethanol
beta-Aminoethyl alcohol
beta-Ethanolamine
beta-Hydroxyethylamine
b-Ethanolamine
b-Hydroxyethylamine
Cholylglycine
Colamine
D Glutamate
D1,3,5(10)-Estratrien-3-ol-17-one
D-2,3-Dihydroxypropanoic acid
D-GlcNAc
D-Glutamate
|
D-Glycerate
D-Glyceric acid
D-GroA
E
E 620
E620
E-620
Envision conditioner PDD 9020
Estrone, (+-)-isomer
Estrone, (8 alpha)-isomer
Estrone, (9 beta)-isomer
Estrovarin
ETA
Ethylolamine
FEMA NO. 3285
Follicular hormone
Folliculin
Glt
Glu
Glusate
Glut
Glutacid
Glutamate
Glutamate, potassium
GLUTAMIC ACID
Glutamic acid, (D)-isomer
Glutamicol
Glutamidex
Glutaminate
Glutaminic acid
Glutaminol
Glutaton
Glycerate
Glycine cholate
Glycinol
Glycocholate
Glycocholate sodium
Glycocholic acid, sodium salt
Glycoreductodehydrocholic acid
Glycylcholate
Glycylcholic acid
Hauck brand OF estrone
Hea
H-Glycinol
Hyrex brand OF estrone
INS NO.620
INS-620
Kestrone
L Glutamate
L Glutamic acid
L-(+)-Glutamate
L-(+)-Glutamic acid
L-a-Aminoglutarate
L-a-Aminoglutaric acid
L-alpha-Aminoglutarate
L-alpha-Aminoglutaric acid
L-Glu
L-Glu|L-glutamate|poly-L-glutamate
L-GLUTAMATE
L-Glutamate, aluminum
L-GLUTAMIC ACID
L-Glutaminate
L-Glutaminic acid
L-Glutaminsaeure
MEA
Monoaethanolamin
MONOETHANOLAMINE
N Acetyl D glucosamine
N-(Carboxymethyl)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-amide
N-(Carboxymethyl)-3α,7α,12α-trihydroxy-5β-cholan-24-amide
N-[(3a,5b,7a,12a)-3,7,12-Trihydroxy-24-oxocholan-24-yl]glycine
N-[(3alpha,5beta,7alpha,12alpha)-3,7,12-Trihydroxy-24-oxocholan-24-yl]glycine
N-[(3Α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]glycine
N-Acetylchitosamine
N-Acetyl-D-glucosamine
N-Choloylglycine
N-Choloyl-glycine
NSC-143503
Oestrone
Olamine
Potassium glutamate
R-Glycerate
R-Glyceric acid
Unigen
Vortech brand OF estrone
Wehgen
Α,β-hydroxypropionate
Α,β-hydroxypropionic acid
Β-aminoethanol
Β-aminoethyl alcohol
Β-ethanolamine
Β-hydroxyethylamine
|
|
37 |
|
D-Tyrosine |
Approved, Experimental, Investigational, Nutraceutical |
Phase 3 |
|
133585-56-5, 60-18-4, 556-02-5 |
1153 6057 |
Synonyms:
(-)-a-Amino-p-hydroxyhydrocinnamate
(-)-a-Amino-p-hydroxyhydrocinnamic acid
(-)-alpha-Amino-p-hydroxyhydrocinnamate
(-)-alpha-Amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamate
(−)-α-amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamic acid
(2S)-2-Amino-3-(4-hydroxyphenyl)propanoate
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-AMINO-3-(4-HYDROXYPHENYL)PROPIONIC ACID
(2S)-2-AZANYL-3-(4-HYDROXYPHENYL)PROPANOIC ACID
(R)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(R)-3-(p-Hydroxyphenyl)alanine
(S)-(-)-Tyrosine
(S)-2-Amino-3-(p-hydroxyphenyl)propionate
(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(S)-3-(p-Hydroxyphenyl)alanine
(S)-a-Amino-4-hydroxybenzenepropanoate
(S)-a-Amino-4-hydroxy-benzenepropanoate
(S)-a-Amino-4-hydroxybenzenepropanoic acid
(S)-a-Amino-4-hydroxy-benzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoate
(S)-alpha-Amino-4-hydroxy-benzenepropanoate
(S)-alpha-amino-4-Hydroxybenzenepropanoic acid
(S)-alpha-Amino-4-hydroxy-benzenepropanoic acid
(S)-Tyrosine
(S)-Α-amino-4-hydroxybenzenepropanoate
(S)-α-amino-4-hydroxybenzenepropanoic acid
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid
2-Amino-3-(4-hydroxyphenyl)propanoate
|
2-Amino-3-(4-hydroxyphenyl)propanoic acid
2-Amino-3-(p-hydroxyphenyl)propionate
2-Amino-3-(p-hydroxyphenyl)propionic acid
3-(4-Hydroxyphenyl)-L-alanine
3-(p-Hydroxyphenyl)alanine
4-hydroxy-L-phenylalanine
6-Hydroxysandoricin
Benzenepropanoate
Benzenepropanoic acid
D-Tyr
D-Tyrosin
FEMA NO. 3736
L Tyrosine
LEVODOPA IMPURITY, L-TYROSINE-
LEVODOPA RELATED COMPOUND L-TYROSINE
L-p-Tyrosine
L-Tyrosin
L-tyrosine
Methyl 2-[5,11-bis(acetyloxy)-13-(furan-3-yl)-16-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.0¹,¹².0³,⁸]heptadecan-7-yl]-2-hydroxyacetic acid
NSC-82624
Para tyrosine
Para-tyrosine
p-Tyrosine
Tirosina
Tyr
Tyrosin
Tyrosine
Tyrosine, L isomer
Tyrosine, L-isomer
Tyrosinum
Y
|
|
38 |
|
Abetimus |
Investigational |
Phase 3 |
|
167362-48-3 |
|
Synonyms:
|
39 |
|
Immunoglobulin A |
|
Phase 3 |
|
|
|
40 |
|
Antibiotics, Antitubercular |
|
Phase 3 |
|
|
|
41 |
|
Protein Kinase Inhibitors |
|
Phase 3 |
|
|
|
42 |
|
Antioxidants |
|
Phase 3 |
|
|
|
43 |
|
Radiation-Protective Agents |
|
Phase 3 |
|
|
|
44 |
|
Phosphodiesterase Inhibitors |
|
Phase 3 |
|
|
|
45 |
|
Vasodilator Agents |
|
Phase 3 |
|
|
|
46 |
|
Platelet Aggregation Inhibitors |
|
Phase 3 |
|
|
|
47 |
|
Protective Agents |
|
Phase 3 |
|
|
|
48 |
|
Insulin, Globin Zinc |
|
Phase 3 |
|
|
|
49 |
|
Insulin |
|
Phase 3 |
|
|
|
Synonyms:
AFREZZA
EXUBERA
HUMULIN
HUMULIN BR
HUMULIN R
HUMULIN R KWIKPEN
HUMULIN R PEN
INS HUMULIN R
INSULIN
INSULIN (HUMAN)
INSULIN BOVINE
INSULIN BOVINE INSULIN
|
INSULIN HUMAN
INSULIN HUMAN (BIOSYNTHESIS)
INSULIN HUMAN (SYNTHESIS)
INSULIN RECOMBINANT HUMAN
INSULIN RECOMBINANT PURIFIED HUMAN
INSUMAN INFUSAT
MYXREDLIN
NOVOLIN
NOVOLIN R
VELOSULIN
VELOSULIN BR
VELOSULIN BR HUMAN
|
|
50 |
|
Vitamins |
|
Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 164)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Normal Oxygenation Maintenance in Intensive Care Unit: Randomized Controlled Trial |
Unknown status |
NCT01319643 |
Phase 4 |
Oxygen |
2 |
Effect of Midazolam on Inflammatory Response and Organ Function in Mechanically Ventilated Sepsis Patients With Different Immune Status. |
Unknown status |
NCT02135055 |
Phase 4 |
Midazolam;Morphine |
3 |
Mesalamine to Reduce T Cell Activation in HIV Infection |
Completed |
NCT01090102 |
Phase 4 |
Mesalamine (5-aminosalicylic acid, Apriso);Placebo |
4 |
Use of Traditional Chinese Medicine (Ren Shen Yang Rong Tang) Against Microinflammation in Hemodialysis Patients: A Quasi-randomized Controlled Trial |
Completed |
NCT02053740 |
Phase 4 |
Add R-S-Y-R-T (500 mg 3 times per day) for 6 months;Routine western medicine |
5 |
Effects of Azithromycin Treatment on Anti-viral Immunity in Patients With Asthma and COPD - A Randomized Double-blind, Placebo-controlled Trial |
Recruiting |
NCT04319705 |
Phase 4 |
Azithromycin;Placebo oral tablet |
6 |
Evaluation of Immune Response to Vaccines in Primary Immune Disorders |
Terminated |
NCT00023504 |
Phase 4 |
|
7 |
Methodology Study to Investigate the Utility of Retroviral Insertion Site Analysis in Samples From Subjects Treated With Strimvelis™ Gene Therapy |
Withdrawn |
NCT03311074 |
Phase 4 |
|
8 |
Effect of Early Oral Colostrum Administration Versus Placebo on the Immune System in Premature Newborns Under 32 Weeks of Gestation: A Randomized Clinical Trial. |
Unknown status |
NCT03578341 |
Phase 3 |
|
9 |
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis |
Completed |
NCT03054428 |
Phase 3 |
Dupilumab;Placebo |
10 |
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 AND DUPILUMAB IN COMPARISON WITH PLACEBO IN ADULT SUBJECTS ON BACKGROUND TOPICAL THERAPY, WITH MODERATE TO SEVERE ATOPIC DERMATITIS |
Completed |
NCT03720470 |
Phase 3 |
PF-04965842 100 mg;PF-04965842 200 mg;Dupilumab;Oral Placebo;Injectable Placebo |
11 |
A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS |
Completed |
NCT03627767 |
Phase 3 |
PF-04965842 100 mg;PF-04965842 200 mg;Placebo |
12 |
Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response. |
Completed |
NCT01472263 |
Phase 3 |
Pentoxifylline;Placebo |
13 |
T-Cell Depletion in Unrelated Donor Marrow Transplantation |
Completed |
NCT00000591 |
Phase 3 |
|
14 |
A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802) |
Completed |
NCT01002742 |
Phase 3 |
Mycophenolate Mofetil;Placebo |
15 |
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Safety and Efficacy Trial of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease |
Completed |
NCT00035308 |
Phase 3 |
Abetimus sodium (LJP 394) |
16 |
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults With Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype |
Recruiting |
NCT05018585 |
Phase 3 |
|
17 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects With Relapsed or Refractory Mantle Cell Lymphoma |
Not yet recruiting |
NCT05431179 |
Phase 3 |
Zilovertamab;Ibrutinib;Placebo |
18 |
In-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic Disorders |
Terminated |
NCT00176826 |
Phase 2, Phase 3 |
Myeloablative conditioning regimen |
19 |
A Non-randomized, Open-label, Phase II Study of Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not Suitable for Transplantation |
Unknown status |
NCT03373019 |
Phase 2 |
Chidamide combined with R-GDP |
20 |
Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia. |
Unknown status |
NCT01579110 |
Phase 2 |
levamisole;Prednisone |
21 |
Multicenter Clinical Trial Evaluating the Immunological Response of Vaccination Against Infection by Human Papillomavirus (HPV) 6, 11, 16, 18 in Girls Receiving Immunosuppressive Therapy. |
Unknown status |
NCT01687192 |
Phase 2 |
|
22 |
Chronic Non-bacterial Osteomyelitis Treated With Pamidronate in a Randomised Placebo Controlled Trial |
Unknown status |
NCT02594878 |
Phase 2 |
Pamidronatdinatrium |
23 |
Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD |
Unknown status |
NCT02519816 |
Phase 2 |
|
24 |
Efficacy and Safety of Transplantation of Autologous Stem Cells Into Pancreatic Artery, Combined With Immunomodulation for the Treatment of Type 1 Diabetes Mellitus |
Completed |
NCT02644759 |
Phase 1, Phase 2 |
|
25 |
Phase II Study of First Line Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide |
Completed |
NCT02966301 |
Phase 2 |
Arsenic Trioxide Injectable Solution |
26 |
High-dose Post-transplantation Cyclophosphamide as Graft Versus-host Disease Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation |
Completed |
NCT02294552 |
Phase 2 |
Cyclophosphamide;Busulfan;Fludarabine monophosphate;Tacrolimus;Mycophenolate mofetil |
27 |
A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd® Therapy Administered Into Lymph Nodes Combined With Oral Vitamin D to Investigate the Impact on the Progression of Type 1 Diabetes |
Completed |
NCT03345004 |
Phase 2 |
|
28 |
A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults With Inadequately Controlled Asthma on Inhaled Corticosteroids and at Least One Additional Asthma Controller (CASCADE) |
Completed |
NCT03688074 |
Phase 2 |
|
29 |
Benralizumab Regulates Atopic Dermatitis Through Effects on Eosinophils, Basophils and Innate Lymphoid Type 2 Cells. |
Completed |
NCT03563066 |
Phase 2 |
Benralizumab;Placebo Control |
30 |
Multicenter Clinical Trial Phase I / II Randomized, Placebo-controlled Study to Evaluate Safety and Feasibility of Therapy With Two Different Doses of Autologous Mesenchymal Stem Cells in Patients With Secondary Progressive Multiple Sclerosis Who do Not Respond to Treatment |
Completed |
NCT01056471 |
Phase 1, Phase 2 |
|
31 |
Extract Allergen From Betula Verrucosa. Test Sensitivity and Specificity of Diagnostic in Prick Test Preparation. |
Completed |
NCT02527187 |
Phase 2 |
|
32 |
Multicenter Clinical Trial Phase I/II Randomized, Controlled, for the Evaluation of Safety and Feasibility of Therapy With Two Different Doses of Allogenic Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease. |
Completed |
NCT01222039 |
Phase 1, Phase 2 |
|
33 |
A Pilot Study of Anakinra in Behcet's Disease (BD) |
Completed |
NCT01441076 |
Phase 1, Phase 2 |
Anakinra |
34 |
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy: a Prospective, Uncontrolled Pilot Study |
Completed |
NCT01727973 |
Phase 1, Phase 2 |
Doxycycline |
35 |
A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab (SAR650984) in Patients Awaiting Kidney Transplantation |
Completed |
NCT04294459 |
Phase 1, Phase 2 |
Isatuximab SAR650984;Acetaminophen (paracetamol) or equivalent;Ranitidine or equivalent;Diphenhydramine or equivalent;Methylprednisolone or equivalent;Montelukast or equivalent |
36 |
A Personalized Randomized Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis |
Completed |
NCT03332225 |
Phase 2 |
Anakinra;Recombinant human interferon-gamma;Placebo |
37 |
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302) |
Completed |
NCT00224874 |
Phase 2 |
Etanercept;Mycophenolate Mofetil;Denileukin Diftitox;Pentostatin |
38 |
A Single Centre, Open-label, Single-group Exploratory Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy |
Recruiting |
NCT04663204 |
Phase 2 |
Sparsentan |
39 |
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity |
Recruiting |
NCT04339777 |
Phase 2 |
Busulfan test dose;Fludarabine;Busulfan;Alemtuzumab;Tacrolimus (Tacro);Mycophenolate mofetil (MMF);Cyclophosphamide (Cytoxan) |
40 |
A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Peresolimab in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis |
Recruiting |
NCT05516758 |
Phase 2 |
Peresolimab;Placebo |
41 |
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies |
Recruiting |
NCT02579967 |
Phase 2 |
Immunosuppression Only Conditioning -Closed with amendment L;Reduced Intensity Conditioning;Myeloablative Conditioning-Closed with amendment L;GVHD Prophylaxis |
42 |
Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma |
Recruiting |
NCT02690545 |
Phase 1, Phase 2 |
|
43 |
Administration of Autologous CAR-T Cells Targeting the CD19 Antigen and Containing the Inducible caspase9 Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia |
Recruiting |
NCT03016377 |
Phase 1, Phase 2 |
Rimiducid;Cyclophosphamide;Fludarabine |
44 |
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation |
Recruiting |
NCT03663933 |
Phase 2 |
Immunosuppression Only Conditioning;Reduced Intensity Conditioning;GVHD Prophylaxis |
45 |
The Effect of Subantimicrobial Dose Doxycycline in Mild Thyroid-Associated Ophthalmopathy |
Recruiting |
NCT02203682 |
Phase 2 |
Doxycycline hyclate;Placebo |
46 |
A Phase I/II Trial of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplantation in Children With Non-Malignant Disorders |
Recruiting |
NCT03128996 |
Phase 1, Phase 2 |
RIC regimen;GVHD prophylaxis regimen |
47 |
Phase I/II Randomized Clinical Study of Cycles of a New Formulated FMD in Prefrail Elderly. |
Recruiting |
NCT04928963 |
Phase 1, Phase 2 |
|
48 |
A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19 |
Active, not recruiting |
NCT04365101 |
Phase 1, Phase 2 |
|
49 |
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting |
Active, not recruiting |
NCT03744676 |
Phase 2 |
|
50 |
An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D) |
Not yet recruiting |
NCT05565248 |
Phase 1, Phase 2 |
|
|